Citation Impact
Citing Papers
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
2017
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Systematic review of outpatient services for chronic pain control.
1997
A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management
2019
Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
2018 StandoutNobel
Cell therapy for autoimmune diseases
2007
Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation
2014
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
2008
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
2005
BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists
2006
Imitators of Severe Pre-eclampsia
2009
Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review
2016
Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
2006
MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
2014
Ontology and Function of Fibroblast-Like and Macrophage-Like Synoviocytes: How Do They Talk to Each Other and Can They Be Targeted for Rheumatoid Arthritis Therapy?
2018
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts
2011
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
2008
Macrophage heterogeneity in the context of rheumatoid arthritis
2016
Cancer burden in the year 2000. The global picture
2001 Standout
Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial
2015
Rheumatoid arthritis
2018 Standout
A prospective 2‐year study of 75 patients with adult‐onset septic arthritis
2001
Aurothioglucose Inhibits Murine Thioredoxin Reductase Activity In Vivo
1999
New therapies for treatment of rheumatoid arthritis
2007
Antimalarial drugs in the treatment of rheumatological diseases.
1997
Rheumatoid arthritis
2016 Standout
Powerful placebo: the dark side of the randomised controlled trial
1998
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
2011
Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society
2007 Standout
Meta-analyses to evaluate analgesic interventions: A systematic qualitative review of their methodology
1996
A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis
2009
Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis
2008
Influence of context effects on health outcomes: a systematic review
2001 Standout
A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
2005
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
2011 Standout
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
2003
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
2009
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
2013
Juvenile idiopathic arthritis
2007 Standout
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
2020 Standout
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
2012
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
2006
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
2013
Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial
2015 StandoutNobel
An update on methotrexate
2009
Psoriasis
2021 Standout
Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis
2012
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
2005
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
2011
Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities
2021 Standout
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
2009
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
2013
The Anti-rheumatic Gold Salt Aurothiomalate Suppresses Interleukin-1β-induced Hyaluronan Accumulation by Blocking HAS1 Transcription and by Acting as a COX-2 Transcriptional Repressor
2006
Forget personalised medicine and focus on abating disease activity
2012
The IL-23–IL-17 axis in inflammatory arthritis
2015
Clinical management of psoriatic arthritis
2018
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
INJECTABLE GOLD COMPOUNDS: AN OVERVIEW
1995
IL-6 in Inflammation, Immunity, and Disease
2014 Standout
Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states
2005
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
2005
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
2014
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
1999
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
2013
Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources
2008
RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical Disease Activity Index Categories
2008
Development of quality indicators for monitoring of the disease course in rheumatoid arthritis
2009
Pre-eclampsia
2010 Standout
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
2007
Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study
2016
Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome
2002
Assessing remission in clinical practice
2007
Selenium supplementation acting through the induction of thioredoxin reductase and glutathione peroxidase protects the human endothelial cell line EAhy926 from damage by lipid hydroperoxides
2002
Rheumatoid arthritis
2010 Standout
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
2002
Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
2012
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
2007
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
2010
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
2015
Reactive oxygen species, antioxidants, and the mammalian thioredoxin system1 1This review is based on the licentiate thesis “Thioredoxin reductase—interactions with the redox active compounds 1-chloro-2,4-dinitrobenzene and lipoic acid” by Jonas Nordberg, 2001, Karolinska Institute, Stockholm, ISBN 91-631-1064-4.
2001 Standout
The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis
2016 StandoutNobel
Emerging cell and cytokine targets in rheumatoid arthritis
2013
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Cost‐utility analysis of treatment strategies in patients with recent‐onset rheumatoid arthritis
2009
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
2014
Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer
2009 Standout
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
2016
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
2006 Standout
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
2008
Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis
2021 StandoutNobel
Global cancer statistics in the year 2000
2001 Standout
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
2014
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A production
2010
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
2017
The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care
2009
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
GM-CSF but Not IL-17 Is Critical for the Development of Severe Interstitial Lung Disease in SKG Mice
2014
Sulfasalazine
2005
Atherosclerosis and inflammation: overview and updates
2018
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice
2016 StandoutNobel
Nonpharmacologic Therapies for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline
2007 Standout
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
2000
Reorientation effect in the cadmium isotopes
1970
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Etanercept for the Treatment of Rheumatoid Arthritis
2018
mice: Multivariate Imputation by Chained Equations inR
2011 Standout
Coulomb reorientation of 2+ states in 32S and 112Cd
1971 StandoutNobel
Gold Nanoparticles: A Revival in Precious Metal Administration to Patients
2011 Standout
Disease activity measures for rheumatoid arthritis.
2008
X-Ray Fluorescence Yields, Auger, and Coster-Kronig Transition Probabilities
1972 Standout
Brief Report: T Cell Expression of Granulocyte–Macrophage Colony‐Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity
2014
Mortality in rheumatoid arthritis: 2008 update.
2009
Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis
2017
Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis
2008
Radioactive atoms
1970
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis
2012
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis
2018 StandoutNobel
Industry sponsorship and research outcome
2017 Standout
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment
2016
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
Works of Duncan Porter being referenced
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
2016
Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice
1999
Myocrisin-mediated oxidative stress
1997
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
2006
Optimising the strategy of care in early rheumatoid arthritis
2010
THE ‘NATURAL’ HISTORY OF ACTIVE RHEUMATOID ARTHRITIS OVER 3–6 MONTHS—AN ANALYSIS OF PATIENTS ENROLLED INTO TRIALS OF POTENTIAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS, AND TREATED WITH PLACEBO
1993
Triple therapy in early active rheumatoid arthritis: A randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies
2008
How low to aim in rheumatoid arthritis? Learning from other disciplines
2013
Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial
2016
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
2004
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
2012
Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis
1997
Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data
2013
Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years
1999
Combination therapy in rheumatoid arthritis--no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy.
1993
Tightening Up? Impact of Musculoskeletal Ultrasound Disease Activity Assessment on Early Rheumatoid Arthritis Patients Treated Using a Treat to Target Strategy
2013
Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?
1993
UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug
2008
Excited states in 111Cd
1968
Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial.
1996
Intensive management of early rheumatoid arthritis: the TICORA and TEAR studies.
2013
Action of sodium aurothiomalate on erythrocyte membrane.
1992
Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
1992
Acute renal failure complicating HELLP syndrome, SLE and anti-phospholipid syndrome: successful outcome using plasma exchange therapy
2003